Breaking Down Zhejiang Ausun Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Zhejiang Ausun Pharmaceutical's numbers demand a close look: Q1 2025 operating income of CNY 307 million (up 1.90% YoY) contrasts with a trailing twelve months revenue of CNY 751.12 million (down 10.07% YoY) and 2024 annual sales of CNY 795.29 million (-2.63% vs. 2023), even as gross margin rose to 61.01% (+2.72 pp) and Q1 net margin hit 38.87% (+1.49 pp); profitability shows a TTM net income of CNY 213.51 million and ROE of 7.96% while liquidity and balance-sheet strength stand out with a conservative debt-to-equity of 0.16, net cash of CNY 758.80 million, current/quick ratios of 2.84/2.13, operating cash flow of CNY 241.67 million and free cash flow of CNY 143.80 million-supported by an Altman Z‑Score of 7.75-but valuation multiples are rich (TTM P/E 44.85, forward P/E 37.47, P/S 10.95, P/B 3.50, EV/EBITDA 33.73, EV/FCF 51.92) and risks from regulation, competition and product concentration sit alongside growth levers such as CNY 197 million cardiovascular sales, CNY 120 million anti‑tumor sales and the newly registered Imatinib Mesylate Tablets-dive into the full breakdown to parse whether Ausun's premium valuation and cash strength offset slowing revenue and sector pressures

Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) - Revenue Analysis

• Q1 2025 operating income: CNY 307 million (+1.90% YoY)
• TTM revenue (Sep 2025): CNY 751.12 million (-10.07% YoY)
• 2024 annual revenue: CNY 795.29 million (-2.63% vs. 2023)
• 12-month revenue growth: -10.07%; 3-year average: +10.30%; 5-year average: +19.60%
• Primary near-term headwinds: increased competition and market saturation
• Revenue per share: declining over the past 12 months (impacting shareholder revenue allocation)

Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) - Profitability Metrics

The company's recent profitability profile shows strong gross and net margins in Q1 2025 alongside mixed trailing performance. Key headline figures:

• Q1 2025 gross profit margin: 61.01% (up 2.72 percentage points YoY)
• Q1 2025 net profit margin: 38.87% (up 1.49 percentage points YoY)
• TTM net income as of Sep 2025: CNY 213.51 million (decrease YoY)
• Reported ROE: 7.96%
• Reported net profit margin (period/aggregate): 24.61%

Interpretation and drivers to monitor:

• Margin expansion in Q1 2025 suggests improved pricing or product mix and/or lower COGS relative to revenue.
• High Q1 net margin (38.87%) may reflect one-off items, seasonal results, or non-recurring income - compare quarterly composition.
• TTM net income decline to CNY 213.51 million indicates that full-year profitability weakened despite strong Q1 performance; management commentary and line-item P&L changes should be reviewed.
• ROE of 7.96% signals moderate returns on equity - not low enough to be alarmingly poor, but below high-growth sector peers; watch leverage, equity base growth, and profit sustainability.
• Net profit margin of 24.61% shows healthy conversion of revenue to profit on an aggregate basis, but the gap between aggregate margin and Q1 results implies volatility across periods.
• Potential causes for lower TTM net income include rising operating expenses, increased competition pressuring volumes or prices, higher R&D/SG&A spend, or one-off charges.

For deeper context on ownership, major buyers, and investor positioning that can affect future profitability expectations, see: Exploring Zhejiang Ausun Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) Debt vs. Equity Structure

• Debt-to-equity ratio: 0.16 - indicates limited reliance on borrowed funds versus shareholder equity.
• Total debt: CNY 376.63 million - the absolute debt burden in the context of company size and cash balances.
• Net cash position: CNY 758.80 million - cash and equivalents exceed total debt by a wide margin.
• Current ratio: 2.84 - short-term assets are nearly three times short-term liabilities, supporting operational resilience.
• Quick ratio: 2.13 - liquid assets (ex-inventories) comfortably cover current liabilities.
• Interest coverage ratio: 18.25 - operating earnings cover interest expense by over 18x, reducing default risk.

• Capital flexibility: Net cash and low leverage enable strategic investments, R&D spend, or opportunistic M&A without immediate financing pressure.
• Downside protection: Strong liquidity ratios and an elevated interest coverage reduce bankruptcy and liquidity stress risk.
• Return considerations: Conservative financing may limit financial engineering upside (e.g., tax benefits of debt) but prioritizes stability.

Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) - Liquidity and Solvency

• Current ratio: 2.84 - comfortably above 1, indicating coverage of short-term liabilities.
• Quick ratio: 2.13 - strong immediate-liquidity buffer excluding inventories.
• Net cash position: CNY 758.80 million - net cash on the balance sheet to support flexibility.
• Operating cash flow (last 12 months): CNY 241.67 million - consistent cash generation from operations.
• Free cash flow: CNY 143.80 million - available for growth investment, deleveraging or returns to shareholders.
• Altman Z-Score: 7.75 - indicates very low bankruptcy risk and strong solvency.

• Liquidity posture supports operational continuity and tactical M&A or capex spending without immediate financing needs.
• High quick ratio reduces reliance on inventory turns to meet obligations - important in pharma where inventory cycles can vary.
• Positive free cash flow and net cash position create optionality for R&D spend, commercialization of products, or shareholder-friendly actions.
• Altman Z-Score well above distress thresholds corroborates low solvency risk and creditor confidence.

Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) - Valuation Analysis

• High P/E and P/S: implies growth expectations; sensitivity to earnings misses is elevated.
• Forward P/E < TTM P/E: market anticipates margin expansion or revenue-driven EPS growth.
• Elevated EV multiples: less cushion if EBITDA or FCF compress; valuation contingent on delivery of growth.
• P/B > 1: market values intangibles and future returns above net asset base.

• Justifiers: strong product pipeline, favorable regulatory environment, pricing power, scalable manufacturing or specialized therapeutic positioning.
• Risks: clinical/regulatory setbacks, pricing pressure, competition, margin contraction, or macro-driven demand shocks.

Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) - Risk Factors

• Regulatory and compliance risk: The pharmaceutical sector operates under strict regulatory oversight (drug approvals, GMP inspections, post-market surveillance). Adverse regulatory findings, changes in approval timelines, or stricter clinical/trial requirements can delay product launches and increase compliance costs.
• Competitive pressure: Domestic generics producers, branded multinational pharma, and biotech entrants increase pricing pressure and can erode market share, particularly in segments where Ausun's products lack strong differentiation.
• Raw material and FX volatility: Fluctuations in active pharmaceutical ingredient (API) prices and the yuan's exchange rate versus the USD/EUR can materially affect input costs and imported materials, squeezing margins when cost pass-through is limited.
• Product concentration risk: Heavy reliance on a few core products or product families can magnify revenue volatility if demand or pricing for those products weakens, faces patent/challenge issues, or encounters quality/recall events.
• Policy and reimbursement changes: Shifts in national/local healthcare policy, centralized procurement, or adjustments to drug reimbursement lists and pricing ceilings can reduce revenues or force margin compressions.
• Operational and supply-chain risk: Manufacturing disruptions (quality control failures, capacity bottlenecks), single-sourced suppliers, logistics interruptions, or raw-material shortages can hamper production and delivery, impacting sales and customer relationships.

• Regulatory scenarios to monitor:
  • Changes to NMPA guidelines, GMP inspection frequency, or accelerated post-market surveillance intensity.
  • Increased requirements for clinical data or bioequivalence for generics could raise costs and approval timelines.
• Competitive dynamics to watch:
  • Centralized procurement outcomes and price-volume contracts that favor lower-cost producers.
  • New product launches by large multinationals or domestic peers targeting the same therapeutic areas.
• Operational risk factors:
  • Supplier single points of failure for key APIs or excipients.
  • Capacity utilization rates-sudden demand surges or plant shutdowns could disrupt supply.
• Financial sensitivity drivers:
  • How a 10-20% rise in key API costs would compress gross margin given current cost structure.
  • Impact of a 5-10% depreciation of CNY on imported-material costs and reported margins.

• Mitigating indicators investors should track:
  • R&D pipeline progress and diversification beyond top-selling products.
  • CapEx and quality-investment disclosures addressing GMP, capacity and supply-chain resilience.
  • Debt maturities and cash runway to manage regulatory remediation or market shifts.
  • Changes in product mix and revenue by geography to assess FX and policy exposure.

Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) - Growth Opportunities

Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) is positioning for accelerated growth through portfolio expansion, capacity build-out and targeted R&D. Key therapeutic drivers in 2024 include cardiovascular and oncology segments with demonstrable revenue traction and newly secured product registrations.

• Cardiovascular product sales: CNY 197 million in 2024, reflecting strong market acceptance and stable demand in chronic disease management.
• Anti-tumor product sales: CNY 120 million in 2024, supported by new product introductions and growing oncology channel uptake.
• Imatinib Mesylate Tablets: successful registration enables entry into oncology markets and potential formulary placements.

Strategic capacity and commercialization moves:

• New production capacities under development to scale supply for cardiovascular and oncology lines - reducing lead times and enabling volume-based pricing.
• Process development and advanced chemical synthesis capabilities aimed at complex APIs, improving margins and barrier to entry for competitors.
• Ongoing R&D programs focused on both innovative molecules and lifecycle management of existing assets to extend product lifecycles.
• Targeted partnerships and distribution collaborations to broaden market reach domestically and in select export markets.

Investors should monitor capacity commissioning timelines, commercialization uptake for Imatinib Mesylate Tablets, R&D milestone cadence and partnership announcements as catalysts for revenue and margin improvement. Additional company background and context are available here: Zhejiang Ausun Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money